Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2018/11JUI/248 | Registry Identifier | Ethics Committee Approval | |
| B403201836842 | Other Identifier | Belgium Registration number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to collect blood samples, as well as tumor tissue for genetic analysis. The collection of samples will allow the creation of a plasma bank. Targeted individuals are cancer patients of all types, treated with immunotherapy or targeted therapy.
Immunotherapy or targeted agents will be administered according to standard of care and reimbursement modalities in Belgium. Targeted agents will be administered according to manufacturer's instructions.
With the aim to identify predictive markers of response to treatment or possible resistance mechanism, the plasma samples and the tumor samples will be used for genetic analysis, for example but not limited to, whole exome sequencing. This may lead to the discovery of some germinal mutations implicated in other diseases than cancer.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MOLECULAR TARGETED THERAPIES | Experimental | Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium. Targeted agents will be administered according to manufacturer's instructions. |
|
| IMMUNOTHERAPY | Experimental | Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Immunotherapeutic Agent | Drug | Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium. |
|
| Measure | Description | Time Frame |
|---|---|---|
| efficacy of treatment against Cancer | Efficacy will be determined in terms of overall responses according to standard practice by the local investigator. Disease and response assessments are defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months |
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival (OS) | Overall survival is defined as the time from the date of inclusion to the date of death from any cause or to the date of last follow-up (in exceptional cases where it is impossible to document the date of death). Every effort should be made to document the cause of death. | From date of randomization until the date of first documented progression assessed up to 120 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cliniques Universitaires Saint-Luc | Brussels | 1200 | Belgium |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The trial will include patients with any type of cancer treated with one of the following regimens after signing of the patient's informed consent:
Not provided
Not provided
Masking and allocation tbc
Not provided
| Molecular Target | Drug | Targeted agents will be administered according to standard of care and reimbursement modalities in Belgium. Targeted agents will be administered according to manufacturer's instructions. |
|
| Progression free survival | Progression free survival (PFS) will be measured from the date of inclusion to the date of progression or death, whatever the cause. Progression will be defined according to the RECIST criteria. | From date of randomization until the date of first documented progression , assessed up to 120 months |
| Objective tumor response | Objective tumor response will be measured according to the RECIST 1.1 criteria. | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months |
| ID | Term |
|---|---|
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000276 | Adjuvants, Immunologic |
| C000723989 | Rv1579c phage protein, Mycobacterium tuberculosis |
| ID | Term |
|---|---|
| D007155 | Immunologic Factors |
| D045505 | Physiological Effects of Drugs |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
Not provided
Not provided